Chikungunya Vaccine

Death from chikungunya is rare but it can cause severe health issues in some people. Here are more details about the illness, its symptoms, and prevention methods

The vaccine completed standard pre-clinical studies, and an optimum immune response was elicited by the adjuvant vaccine in phase-1 trials in India

Chikungunya is a dreaded infection transmitted through the bite of mosquito

BS ReporterHyderabad, 6 June: Hyderabad-based vaccine manufacturer Bharat Biotech announced today that the phase 1 of human clinical trials of the indigenously developed Chikungunya vaccine was underway in India to evaluate the vaccine's safety, tolerability and immunogenicity . The placebo controlled study involving 60 healthy volunteers would test escalating doses of the vaccine in prime-boost regimen, the company informed.Bharat Biotech developed the CHIKV vaccine using an isolate of the virus from Indian epidemic. The inactivated virus vaccine developed by the in-house R&D was found to be safe and immunogenic in pre-clinical animal testing, according to the company.After successful completion of product development and pre-clinical testing, the candidate vaccine was approved by the DCG(1) for phase 1 clinical trials in 2016."Chikungunya is one among the modern day's most dreaded virus, and developing an efficient vaccine to prevent it means a lot to people at risk for the ...